Conagra's volume-first decade ended in a $1.92B loss and a halved dividend

In July 2026 Conagra Brands — maker of Banquet, Slim Jim, Marie Callender's and Reddi-wip — reported a net loss of $1.92 billion for the 53 weeks ended 31 May, driven by $2.0 billion of non-cash goodwill and brand impairment charges: $215 million against Grocery & Snacks and $1.75 billion against Refrigerated & Frozen, triggered by the sustained decline in the company's share price and market value.

Full-year sales fell 2.9 per cent to $11.28 billion and the company swung to a $1.63 billion operating loss from a $1.36 billion profit a year earlier. The board halved the quarterly dividend to 17.5 cents from 35 cents, freeing roughly $335 million a year for debt reduction and reinvestment.

Management's own diagnosis was a strategy problem, not just a market one: the balance between volume and margin 'had become skewed toward volume in recent years, at the expense of profitability', and the company — built in large part through decades of acquisitions under Sean Connolly, CEO since 2015 — carried the goodwill that then had to be written down. The reset landed weeks after John Brase, a packaged-goods veteran from P&G and J.M. Smucker, succeeded Connolly on 1 June 2026.

The first full quarter under Brase (reported 30 September 2026) confirmed the steadying phase: net sales down 1.4 per cent to $2.596 billion, organic sales down 1.1 per cent as volume declines outweighed pricing, and the sharply reduced full-year guidance reaffirmed — organic sales down 1–3 per cent, adjusted EPS of $1.40–1.50. Brase promised 'reducing complexity' in the portfolio, with a strategic review under way.

Volume was defended at the expense of profitability until the market value that anchors goodwill crumbled.

An acquisition-built portfolio of dozens of brands concentrated impairment risk in exactly the divisions that shrank.

A dividend yield near 10 per cent was signalling a payout the shrinking cash flows could not honestly support.

The impairments hit the two biggest categories — frozen meals and snacks — just as those categories stalled industry-wide.

Chasing volume to keep the top line flat while margin erodes just moves the reckoning onto the balance sheet: impairment charges are where a mispriced strategy finally gets invoiced.

Brase reaffirmed the reset guidance for fiscal 2027, is targeting leverage of roughly 3.0x EBITDA using the cash freed by the dividend cut, and has a strategic portfolio review under way; Wall Street carries a consensus Hold with price targets of $12–16.